Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
Provided By PR Newswire
Last update: Nov 14, 2024
— Improved loss from operations by 31% —
— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections —
Read more at prnewswire.com
